Treatment patterns and deep molecular response in chronic phase – chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study

Jorge E. Cortes,Lynn Huynh,Estella Mendelson,Patricia Brandt,Darshan Dalal,Maral DerSarkissian,Diego Cortina,Sahil Narkhede,Mei Sheng Duh

Treatment patterns and deep molecular response in chronic phase – chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study

2019

Jorge E. Cortes
Lynn Huynh
Estella Mendelson
Patricia Brandt
Darshan Dalal
Maral DerSarkissian
Diego Cortina
Sahil Narkhede
Mei Sheng Duh

AbstractAchievement of MR4.5 (BCR-ABL1 ≤ 0.0032% on international scale) is an important goal of tyrosine kinase inhibitor (TKI) treatment for patients with chronic myeloid leukemia (CML). This stu...

Keywords:

Medicine
Oncology
Chronic phase chronic myeloid leukemia
Diabetes mellitus
Myeloid leukemia
Tyrosine-kinase inhibitor
Dasatinib
Nilotinib
Molecular Response
Internal medicine
Immunology
chart review
multi country

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations